|Chemical and physical data|
|Molar mass||146.3 kg/mol (peptide) g·mol−1|
|(what is this?)|
A phase III clinical trial of gantenerumab was stopped early because of a lack efficacy. Gantenerumab is also being evaluated in younger patients at high risk of developing Alzheimer's disease but after five years of treatment, the drug did little to slow cognitive decline in patients.
- "Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab" (PDF). American Medical Association.
- "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization. Archived from the original (PDF) on 2012-02-11.
- Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. (January 2018). "The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset". Expert Opinion on Biological Therapy. 18 (1): 25–35. doi:10.1080/14712598.2018.1389885. PMID 29037101. S2CID 4795458.
- Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. (December 2017). "A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease". Alzheimer's Research & Therapy. 9 (1): 95. doi:10.1186/s13195-017-0318-y. PMC 5723032. PMID 29221491.
- Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov
- Kolata G (10 February 2020). "An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'". The New York Times.